Impatto economico dell’utilizzo di carbossimaltosio ferrico in pazienti con anemia da carenza di ferro nelle regioni italiane

Journal title MECOSAN
Author/s Carla Rognoni, Rosanna Tarricone, Michela Meregaglia
Publishing Year 2015 Issue 2015/93
Language Italian Pages 16 P. 99-114 File size 1113 KB
DOI 10.3280/MESA2015-023006
DOI is like a bar code for intellectual property: to have more infomation click here

Below, you can see the article first page

If you want to buy this article in PDF format, you can do it, following the instructions to buy download credits

Article preview

FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.

Iron deficiency anemia is the most common form of anemia observed in clinical practice. The infusion of intravenous iron quanhas proved to be safe and effective and to quickly lead patients to normal hemoglobin levels. Starting from the collection of healthcare resources consumption in five Italian hospitals, the economic impact of the management of patients with iron deficiency anemia in Italy on hospitals and regional health systems has been estimated considering different scenarios of utilization of ferric carboximaltose (FCM) and ferric gluconate (FG). Regional reimbursement tariffs have been used to estimate the economic burden from the perspective of the regional systems, while the cost function related to different inputs was used for the hospital perspective. Assuming a full replacement of FG by FCM, the maximum savings achievable by the Italian health system would be approximately 34 million euro. From the hospital perspective, with a single infusion of 1000 mg of FCM, at the current cost of 131,24 €, it is possible to get savings of 75% compared to 16 infusions of FG 62.5 mg each and 50% compared to 8 infusions of two vials of FG each (125 mg). In conclusion, FCM can be considered a cost-saving option, from both regional health systems and hospital point of views, as compared to the currently and widely adopted iron formulation for the treatment of patients with iron deficiency anemia in Italy.

Keywords: Iron deficiency anemia, ferric carboxymaltose, ferric gluconate, cost, budget impact.

  1. Aronoff G.R., Bennett W.M., Blumenthal S. et al. (2004). Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney International, 66: 1193-1198. DOI: 10.1111/j.1523-1755.2004.00872.x
  2. Auerbach M., Ballard H. (2010). Clinical use of intravenous iron: administration, efficacy, and safety. Hematology ASH Education Program, 4 (1): 338-347. DOI: 10.1182/asheducation-2010.1.338
  3. Bager P., Dahlerup J.F. (2010). The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. Journal of Crohn’s and Colitis, 4 (4): 427-30. DOI: 10.1016/j.crohns.2010.01.007
  4. Charytan C., Schwenk M.H., Al-Saloum M.M. et al. (2004). Safety of iron sucrose in hemodialysis
  5. patients intolerant to other parenteral iron products. Nephron Clinical Practice, 96 (2): c63-c66.
  6. DOI: 10.1159/000076401
  7. Chertow G.M., Mason P.D., Vaage-Nilsen O. et al. (2004). On the relative safety of parenteral iron
  8. formulations. Nephrology Dialysis Transplantation, 19: 1571-1575. DOI: 10.1093/ndt/gfh185
  9. Eschbach J.W., Egrie J.C., Downing M.R. et al (1987). Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. The New England Journal of Medicine, 316: 73-78. DOI: 10.1056/nejm198701083160203
  10. Evstatiev R., Marteau P., Iqbal T. et al. (2011). FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology, 141: 846-853 (e1-2). DOI: 10.1053/j.gastro.2011.06.00
  11. Folkert V.W., Michael B., Agarwal R. et al. (2003). Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher dose (≥ 250 mg) administration. American Journal of Kidney Diseases, 41: 651-657. DOI: 10.1053/ajkd.2003.50141
  12. Fragoulakis V., Kourlaba G., Goumenos D. et al. (2012). Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece. Journal of ClinicoEconomics and Outcomes Research, 4: 127-34. DOI: 10.2147/ceor.s3051
  13. Gutzwiller F.S., Schwenkglenks M., Blank P.R. et al. (2012). Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. European Journal of Heart Failure, 14 (7): 782-90. DOI: 10.1093/eurjhf/hfs083
  14. Hayat A. (2008). Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clinical Medicine and Research, 6: 93-102. DOI: 10.3121/cmr.2008.811
  15. Kulnigg S., Stoinov S., Simanenkov V. et al. (2008). A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled
  16. trial. American Journal of Gastroenterology, 103: 1182–1192. DOI: 10.1111/j.1572-0241.2007.01744.x
  17. Moore R.A., Gaskell H., Rose P. et al. (2011). Meta- analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disorders, 11: 4. DOI: 10.1111/j.1572-0241.2007.01744.x.DOI:10.1186/1471-2326-11-4
  18. Qunibi W.Y., Martinez C., Smith M. et al. (2010). A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysisdependent chronic kidney disease patients. Nephrology Dialysis Transplantation, 26: 1599-1607. DOI: 10.1093/ndt/gfq613
  19. Revised European Best Practice Guidelines For The Management Of Anaemia In Patients With Chronic Renal Failure. Section II: Targets For Anaemia Treatment (2004). Nephrology Dialysis Transplantation, 19 (2): S6-S15. DOI: 10.1093/ndt/gfh1025
  20. Tagboto S., Cropper L., Turner J. et al. (2009). The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients. Journal of Renal Care, 35: 18-23. DOI: 10.1111/j.1755-6686.2009.00075.x
  21. Van Wyck D.B., Roppolo M., Martinez C.O. et al. (2005). A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney International, 68: 2846-2856. DOI: 10.1111/j.1523-1755.2005.00758.x
  22. Van Wyck D.B., Martens M.G., Seid M.H. et al. (2007). Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstetrics & Gynecology, 110: 267-278. DOI: 10.1097/01.aog.0000275286.03283.18
  23. Van Wyck D.B., Mangione A., Morrison J. et al. (2009). Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a
  24. randomized, controlled trial. Transfusion, 49: 2719-2728. DOI: 10.1111/j.1537-2995.2009.02327.x

  • Ferric Carboxymaltose in the treatment of chemotherapy-induced anaemia: an effective, safe and cost- sparing alternative to blood transfusion Joana Marinho, Inês Leão, Sandra Custódio, Enrique Dias, António Moreira Pinto, Telma Costa, Andreia Capela, Margarida Dias, Henrique Coelho, Ângela Cunha, Ana Macedo, Anabela Amarelo, Ana Joaquim, in Scientific Reports 20410/2019
    DOI: 10.1038/s41598-019-56999-3

Carla Rognoni, Rosanna Tarricone, Michela Meregaglia, Impatto economico dell’utilizzo di carbossimaltosio ferrico in pazienti con anemia da carenza di ferro nelle regioni italiane in "MECOSAN" 93/2015, pp 99-114, DOI: 10.3280/MESA2015-023006